There are many questions yet to be answered about neurologic diseases. Why does one mutated copy of a gene cause disease despite the presence of a normal copy on the other chromosome? How can the disease process itself be quite slow and manifest itself clinically as a late-onset neurodegenerative disease? If the mutant gene is expressed in all neurons and other bodily tissues, why is it that only some neurons degenerate while others are spared? What can we do to spare the progression of these diseases and eventually prevent neurodegeneration? A 10-to 20-year delay of symptoms would dramatically improve daily life, even if there is never really a cure for these diseases. Once researchers thoroughly understand the molecular basis of these disorders, they will be able to specifically target processes that go awry for therapeutic intervention.
The spinocerebellar ataxias are a group of diseases characterized by loss of balance and coordination. Although these are the features common to all the ataxias, the initial symptoms can vary greatly. An affected individual might first notice some slight difficulty maintaining balance. Others might note that their speech is becoming slurred or that their eyes suffer involuntary spasms. Some acquire a tremor; others may lose their sight or hearing. Then they develop the characteristic wide-based ataxic gait. Despite the varied onset, the end is the same: after 10 to 15 years of progressively worsening symptoms, patients die because they are no longer able to swallow or breathe. Studies of families with spinocerebellar ataxia type 1 illuminated two important facts about this group of diseases. First, the disease is autosomal dominant: each child of an affected parent has a 50% chance of inheriting the disease (Fig. 1) . Second, each successive generation affected by spinocerebellar ataxia type 1 experiences anticipation; i.e., they will develop a more severe form of the disease at an earlier age. The first generation may display symptoms only when they reach their seventies or eighties; the next generation to be affected will develop symptoms earlier, perhaps in their fifties; this pattern continues until children are developing the disease in their teens or even infancy, and dying within a few years.
So far researchers have identified 10 distinct spinocerebellar ataxias, and have located the precise gene responsible for the disease in 7 of these disorders. Moreover, we know the nature of the mutation that causes trouble: instability in a triplet-repeat tract. The triplet repeat involved in the ataxias is a row of three nucleotide bases (cytosine, adenine, guanine) in the DNA that spell out CAG over and over and encode the amino acid glutamine. In normal genes, CAG may be repeated from 6 to 35 times, but mutant genes are expanded well beyond their normal length, encompassing 40 to more than 100 triplets. Because a number of neurodegenerative disorders, including Huntington's disease, share this expansion of the polyglutamine tract, they are known collectively as polyglutamine or triplet repeat diseases. Interestingly, the longer the expansion, the more severe the disease, and the earlier its onset. The repeat is unstable and expands as it is passed from one generation to the next, particularly if the affected parent is the father-this explains the phenomenon of anticipation mentioned earlier. Figure 2 shows the strong inverse correlation between age of onset and number of repeats.
So, what are the implications of finding the gene for several of these disorders and having the mutation in hand? The first ones are clinical. There is a simple and accurate diagnostic test to identify patients with these various disorders. Before 1993, many of these patients had to undergo extensive diagnostic workups, magnetic resonance imaging (MRI), computed axial tomography (CAT) scans, nerve conduction studies, and biopsies. Patients can now have a simple blood test to determine which of the ataxia subtypes they might have, and can be counseled accordingly. Greater un-
